Home
 /
Papers
 /
Cell Biology
 /
JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells
Preprint
Open access
V1
Top 1% · Validated by QED

JAK2 signalling to HNRNPA1 represses retrotransposon activity in haematopoietic stem cells

Jeremy W. Deuel, Andrejs Makarovs, Sheidasadat Goosheh +12 more
July 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.07.07.663405
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Cell Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By linking cytokine signalling to retrotransposon repression via JAK2-mediated HNRNPA1 phosphorylation, this work overturns the view that adult stem cell genome protection is constitutive, revealing it as dynamically coordinated with cellular state and proliferative signals.

QED claims analysis

Summary

Thrombopoietin signaling through JAK2 directly phosphorylates HNRNPA1 at tyrosines 289 and 295, establishing a cytokine-responsive pathway that represses retrotransposon expression and protects haematopoietic stem cells from insertional mutagenesis, thereby linking cellular signaling state with genome stability through dynamic regulation of retrotransposon activity.

See full analysis
Main Claim 1 –

Somatic retrotransposition mutates HSCs, but less than epithelium

Supporting evidence

  • HNRNPA1 phosphorylation prevents in vivo IAP insertional mutagenesis
Main Claim 2 –

THPO–JAK2 signalling represses ERV, LINE and SINE expression

Main Claim 3 –

JAK2 directly phosphorylates HNRNPA1 at Y289 and Y295

Supporting evidence

  • HNRNPA1 Y289/Y295 phosphorylation is required for HSC retrotransposon repression
  • HNRNPA1 phosphorylation suppresses LINE retrotransposition in vitro

Abstract

Retrotransposon expression must be tightly controlled, particularly in long-lived multipotent stem cells, to prevent deleterious consequences including insertional mutations. Several mechanisms are known to repress retrotransposon transcription during development which are generally thought to persist thereafter. However, integration of retrotransposable elements into host genomes has also provided a major source of genetic variation across evolution. This has generated many sequences that have acquired advantageous host functions, but little is known about retrotransposon expression and mobility in adult stem cells or about how these processes might be dynamically regulated. Here we describe the landscape of somatic retrotransposition in haematopoietic stem cells and identify a previously unrecognised pathway which links cytokine signalling, RNA-modulating HNRNP complexes and repression of retrotransposon activity. Activation of JAK2, by thrombopoietin or gain-of-function JAK2 mutations, triggers tyrosine phosphorylation of HNRNPA1 that represses expression of ERVs, LINEs and SINEs and reduces insertional mutagenesis. This pathway coordinates retrotransposon activity with cellular context and state and provides a mechanism for protecting the haematopoietic stem cell genome.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?